Delay Progression: Eisai Co and Percent Biogen

delay progression: Shares in the company rose more than 3 percent, according to The Japan Times. Biogen has partnered with Japan's Eisai Co. to develop aducanumab as well as BAN2401, which works in a similar way. Experts had been watching closely for any statistical abnormalities or excess safety issues that would affect how the drug is reviewed by the U.S. Food and Drug Administration FDA . If approved, aducanumab would be the first treatment designed to delay progression of the fatal, mind-robbing disease for millions of patients. ; Biogen's fairly neutral showing, and supportive comments from a panel of experts chosen by the company, buoyed investor hopes that the treatment has a reasonable shot at approval. The reaction from other scientists attending the meeting, however, was more mixed, with some suggesting the company should do another trial. Biogen made the argument that response to the therapy was related to cumulative dose how much drug was received over the course of the study, said Dr. It was a well-curated presentation. (news.financializer.com). As reported in the news.